
Francesco Longo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2961354/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Frontiers in Molecular Neuroscience, 2014, 7, 49.	2.9	82
2	Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimer's disease. Science Signaling, 2021, 14, .	3.6	75
3	Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice. Acta Neuropathologica Communications, 2017, 5, 22.	5.2	73
4	Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice. Science Signaling, 2017, 10, .	3.6	73
5	Cognitive Impairment and Dentate Gyrus Synaptic Dysfunction in Experimental Parkinsonism. Biological Psychiatry, 2014, 75, 701-710.	1.3	56
6	Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Neurobiology of Disease, 2014, 71, 62-73.	4.4	48
7	Cell-type-specific drug-inducible protein synthesis inhibition demonstrates that memory consolidation requires rapid neuronal translation. Nature Neuroscience, 2020, 23, 281-292.	14.8	40
8	UPF2 leads to degradation of dendritically targeted mRNAs to regulate synaptic plasticity and cognitive function. Molecular Psychiatry, 2020, 25, 3360-3379.	7.9	38
9	Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model. Neuropsychopharmacology, 2019, 44, 324-333.	5.4	37
10	Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. Neurobiology of Disease, 2016, 89, 55-64.	4.4	24
11	Cell-type-specific disruption of PERK-elF2α signaling in dopaminergic neurons alters motor and cognitive function. Molecular Psychiatry, 2021, 26, 6427-6450.	7.9	18
12	Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain. Neuropsychopharmacology, 2017, 42, 1491-1501.	5.4	15
13	Reciprocal control of translation and transcription in autism spectrum disorder. EMBO Reports, 2021, 22, e52110.	4.5	15
14	Leucineâ€rich repeat kinase 2 (<scp>LRRK</scp> 2) inhibitors differentially modulate glutamate release and Serine935 <scp>LRRK</scp> 2 phosphorylation in striatal and cerebrocortical synaptosomes. Pharmacology Research and Perspectives, 2019, 7, e00484.	2.4	14
15	Genetic removal of p70 S6K1 corrects coding sequence length-dependent alterations in mRNA translation in fragile X syndrome mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	14
16	Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity. Materials Science and Engineering C, 2015, 48, 294-300.	7.3	11
17	l-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter. Brain Research, 2021, 1768, 147583.	2.2	9
18	Inositol polyphosphate multikinase mediates extinction of fear memory. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2707-2712.	7.1	7

#	Article	IF	CITATIONS
19	Key role for hypothalamic interleukin-6 in food-motivated behavior and body weight regulation. Psychoneuroendocrinology, 2021, 131, 105284.	2.7	6